Performance of commercial SARS-CoV-2 wild-type and Omicron BA.1 antibody assays compared with pseudovirus neutralization tests

BACKGROUND: Commercially available ELISA-based antibody tests are used to approximate vaccination success against SARS-CoV-2 in at-risk patients, but it is unclear whether they correlate with neutralization of the Omicron variant. METHODS: 269 serum samples of a cohort of 44 non-immunosuppressed par...

Descripción completa

Detalles Bibliográficos
Autores principales: Habermann, E., Frommert, L.M., Ghannam, K., Nguyen My, L., Gieselmann, L., Tober-Lau, P., Klotsche, J., Arumahandi de Silva, A.N., ten Hagen, A., Zernicke, J., Kurth, F., Sander, L.E., Klein, F., Burmester, G.R., Biesen, R., Albach, F.N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10251723/
https://www.ncbi.nlm.nih.gov/pubmed/37354690
http://dx.doi.org/10.1016/j.jcv.2023.105518

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10251723/
https://www.ncbi.nlm.nih.gov/pubmed/37354690
http://dx.doi.org/10.1016/j.jcv.2023.105518

Ejemplares similares